Research programme: beta-elemene nano-emulsion formulation - ADVENTRX PharmaceuticalsAlternative Names: ANX 570; Beta-elemene - ADVENTRX Pharmaceuticals; Elemene - ADVENTRX Pharmaceuticals; SDP-111; β-elemene - ADVENTRX Pharmaceuticals
Latest Information Update: 30 Oct 2008
At a glance
- Originator ADVENTRX Pharmaceuticals
- Class Antineoplastics; Sesquiterpenes; Small molecules
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Jan 2007 ANX 570 is available for licensing (http://www.adventrx.com)
- 28 Apr 2006 SD Pharmaceuticals has been acquired by ADVENTRX Pharmaceuticals
- 12 Apr 2006 Preclinical trials in Cancer in USA (IV)